Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 19885926.
- Also identified by DOI 10.1002/hed.21239.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this study was to evaluate the significance of nuclear factor-kappa B (NF-kappaB) expression as a marker of radioresistance in early-stage laryngeal cancer. Thirty-five patients with local recurrence and 70 case-matched patients without local recurrence were entered in this study. NF-kappaB expression was compared with Bcl-2 and epidermal growth factor (EGF) receptor expression by immunohistochemistry, using pretreatment biopsy specimens. The prognostic value of NF-kappaB was also evaluated. Twenty-nine recurrent tumors were compared with pretreatment tumors. NF-kappaB expression in pretreatment tumors significantly correlated with local tumor control (p = .01), but bcl-2 and EGF receptor expression did not. Only NF-kappaB expression showed prognostic significance for local tumor control in both univariate and multivariate analyses (p = .008 and .04, respectively). NF-kappaB expression was markedly enhanced in 23 of 29 (80%) recurrent tumors. NF-kappaB expression may be a novel marker of radioresistance in early-stage laryngeal cancer.
Medical subject headings
- Carcinoma, Squamous Cell
- Laryngeal Neoplasms
- NF-kappa B
- Radiation Tolerance